Cycling-Based Aerobic Exercise Intervention for Individuals With Chemotherapy-Induced Peripheral Neuropathy (CIPN)

ConditionsCancerAdults
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Alberta

About this trial

CYCLE-CIPN is a proof-of-concept study designed to evaluate whether a prescribed aerobic exercise intervention has the potential to reduce the symptoms and functional impact of CIPN. The small number of participants in the proposed study will allow us to make decisions on the feasibility ("go/no-go") of a future larger-scale trial.

The protocol will assess feasibility and acceptability through recruitment, completion, adherence, program satisfaction, and safety. The study will also evaluate CIPN symptoms using both patient-reported and objective outcome measures, as well as fitness and quality of life outcomes. We aim to recruit 30 participants.

The Health Research Board of Alberta Cancer Committee has approved this study. Participants will participate in a stationary cycling-based aerobic exercise program biweekly for 12 weeks. Exercise sessions will be supervised and progressive, between 30 and 60 minutes each.

Eligibility criteria

Qualifiers

18 years or older

Cancer diagnosis stage I to III

CIPN: grade 1 (mild)

Receiving or have received chemotherapy treatment for cancer

Disqualifiers

Medical conditions that cause additional neuropathy symptoms (i.e. diabetes)

Any uncontrolled medical conditions

Will undergo surgery or radiation therapy during the study period

Are already receiving an aerobic exercise training program

Trial design

Treatments tested in this trial

  • Exercise

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Alberta

Lead sponsor

Cross Cancer Institute

Collaborator